Literature DB >> 21080278

Lentiviral transgenesis.

Terunaga Nakagawa1, Casper C Hoogenraad.   

Abstract

Conventional DNA injection-based methods are successful in generating transgenic animals and have remained nearly unchanged over the last few decades. Lentiviral vectors are alternative powerful tool for generating transgenic animals, in part because of their ability to incorporate into genomic DNA with high efficiency. This chapter describes lentiviral vectors used to generate transgenic mice and rats. We discuss the protocols and methods in high enough detail such that researchers who are accustomed to creating transgenic animals by pronuclear injection can smoothly transition to using lentiviral transgenesis. We will briefly outline the general principle of the lentiviral expression system and focus specifically on the methods used to generate lentiviral vectors, produce lentiviral particles, inject lentivirus into the fertilized oocytes, and transplant them into the pseudopregnant females. In addition to the surgical aspects of the experiment, we will describe methods to produce high titer lentivirus. Finally, we will discuss the limitations of lentiviral transgenesis and summarize information that will be useful for troubleshooting.

Entities:  

Mesh:

Year:  2011        PMID: 21080278     DOI: 10.1007/978-1-60761-974-1_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo.

Authors:  Friederike Herbst; Claudia R Ball; Francesca Tuorto; Ali Nowrouzi; Wei Wang; Oksana Zavidij; Sebastian M Dieter; Sylvia Fessler; Franciscus van der Hoeven; Ulrich Kloz; Frank Lyko; Manfred Schmidt; Christof von Kalle; Hanno Glimm
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

2.  Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Authors:  Min-Wen Ku; Pierre Authié; Maryline Bourgine; François Anna; Amandine Noirat; Fanny Moncoq; Benjamin Vesin; Fabien Nevo; Jodie Lopez; Philippe Souque; Catherine Blanc; Ingrid Fert; Sébastien Chardenoux; Llta Lafosse; Delphine Cussigh; David Hardy; Kirill Nemirov; Françoise Guinet; Francina Langa Vives; Laleh Majlessi; Pierre Charneau
Journal:  EMBO Mol Med       Date:  2021-10-25       Impact factor: 12.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.